GLP-1 users to make up 35% of food and beverage sales by 2030: report
As more consumers take weight loss medications like Ozempic or Wegovy, companies will need to act fast if they want to adapt, according to Circana.
Novo Nordisk GLP-1 fails to slow Alzheimer’s in trials
Novo Nordisk’s GLP-1 drug semaglutide did not demonstrate a statistically significant effect in slowing progression of Alzheimer’s disease in two late-stage clinical trials. According to a Nov. 24 news release from the company, two double-blinded, placebo-controlled phase 3 trials enrolled 3,808 adults ages 55-85 with mild cognitive impairment or mild dementia. Over a two-year period, […]
Redditors Are Buying Eli Lilly And Co (LLY) Ahead of Potential End of AI Trade. Here’s Why
We recently published Top 10 Non-AI Stocks Redditors are Buying Ahead of Potential Bubble Burst. Eli Lilly And Co (NYSE:LLY) is one of the top non-AI stocks redditors are buying. Eli Lilly And Co (NYSE:LLY) recently posted strong quarterly results amid robust growth from its diabetes and weight-loss products. With a diverse portfolio spanning oncology, […]
Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
NATICK, Mass.–(BUSINESS WIRE)—- $ALUR–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced initial results on the combination of the Allurion Program with low-dose tirzepatide therapy to optimize muscle mass and GLP-1 adherence. 76 patients treated with the Allurion Smart Capsule were started on low-dose tirzepatide after […]
Pill form of semaglutide fails to slow Alzheimer’s in large trial
A pill version of semaglutide, the ingredient in Ozempic and Wegovy, did not slow the progress of Alzheimer’s disease, drugmaker Novo Nordisk announced on Nov. 24.
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD – Yahoo
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD Yahoo
GLP-1 Weight-Loss Drug in Pill Form Shows Promise in Trial
By Ernie Mundell HealthDay ReporterTUESDAY, Nov. 25, 2025 (HealthDay News) — New clinical trial results bode well for what could be the first GLP-1…
PrecisionLife and Ovation Partner to Develop Precision Medicine Test to Inform Reimbursement of GLP-1 Anti-Obesity Drugs
Collaboration to support value-based reimbursement models for GLP-1 receptor agonists, optimizing patient outcomes, increasing markets, and healthcare sustainability. OXFORD, England and PORTLAND, ME, Nov. 25, 2025 /PRNewswire/ — Ovation.io, a leading human omics and clinical data…
Two Alzheimer’s Trial Failures Reveal Clinical Challenges
Two major clinical disappointments Johnson & Johnson’s anti-tau antibody and Novo Nordisk’s GLP-1 metabolic therapy underscore just how complex and Alzheimer’s remains.
Gut health, GLP-1 and AI – the issues shaping ingredients and NPD
At the Next Generation Ingredients 2025 conference, speakers from across the industry explored how health innovation and ethical sourcing are shaping consumer expectations. The post Gut health, GLP-1 and AI – the issues shaping ingredients and NPD appeared first on Just Food.